Merck Opens €59 Million CDMO Facility to Address Demand for Critical Cancer Therapies
Expansion doubles production of the most highly potent active pharmaceutical ingredients (HPAPIs)
Merck announced that its Life Science business sector has doubled its high-potent active pharmaceutical ingredients (HPAPI) production capacity with the expansion of its facility in Verona, near Madison, Wisconsin, USA. This new €59 million, 70,000 square foot facility, officially opened, brings 50 new jobs to the area.

Merck KGaA
“There is an increasing demand for HPAPIs due to their effectiveness against cancer at lower doses and the trend towards more targeted therapeutics. Lower-doses of these therapies reduce the negative side effects for patients who are taking on this critical fight,” said Dirk Lange, head of Life Science Services, Life Science, at Merck. “Increasing capacity at our state-of-the-art CDMO facility in Verona, Wisconsin will allow us to meet the need for these key cancer treatment components.”
HPAPIs are a critical element of targeted therapies due to their extremely effective cell-killing abilities at low doses, resulting in reduced side effects for patients. They are used in novel cancer therapies, including antibody drug conjugates (ADCs), which are changing the landscape of cancer treatments.
Most read news
Other news from the department manufacturing
These products might interest you

Pharmaceutical Substances by Thieme Verlag
Look up Industrial Syntheses of 2,600 APIs
Your tool for Syntheses, Patents and Applications – Pharmaceutical Substances

KNAUER IJM NanoScaler by KNAUER
Efficient formulation of lipid nanoparticles for RNA-based therapies
Optimise drug encapsulation from 1 ml to hundreds of millilitres with minimal drug input

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

A sprinkle of platinum nanoparticles onto graphene makes brain probes more sensitive
Merck and Washington University working on diagnostics and treatment of malnutrition - Genome editing to be used in intestinal bacteria research
Biophage Pharma announces sale of Immunotox Labs Division to Validapro BioSciences Inc

Rescue for Sardines and Anchovies: Produce DHA through biotechnology using microalgae
Astex reveals structure of key drug metabolizing enzyme - cytochrome P450 3A4 - in Science
To-BBB technology will be used by MedImmune to evaluate brain drug delivery mechanism
